![Ian Alexander Francis Miscampbell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ian Alexander Francis Miscampbell
Chairman at
Leucid Bio Ltd.
Profile
Ian Alexander Francis Miscampbell is currently the Chairman of Leucid Bio Ltd. and a Director of Adorx Therapeutics Ltd. He is also the Managing Partner of Sixth Element Capital LLP since 2011.
In the past, he worked as the Finance Director of Witham Contract Manufacturing Ltd. in 2007-2008, Director of Crawford Healthcare Ltd. in 2009, and Chief Financial Officer of York Pharma Plc, Microscience Ltd., and Oxford Immunotec Ltd.
Ian Alexander Francis Miscampbell active positions
| Companies | Position | Start |
|---|---|---|
Sixth Element Capital LLP
 Sixth Element Capital LLP Investment ManagersFinance Sixth Element Capital invests in cancer and oncology drug discovery research projects across Europe. The firm provides financing for growth capital requirements with an investment up to £50 million. | Private Equity Investor | 31/07/2011 |
Adorx Therapeutics Ltd.
 Adorx Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research of new therapeutics for cancer based on modulation of the adenosine pathway | Director/Board Member | - |
Leucid Bio Ltd.
 Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that develops next generation CAR-T therapy | Chairman | - |
Former positions of Ian Alexander Francis Miscampbell
| Companies | Position | End |
|---|---|---|
Crawford Healthcare Ltd.
 Crawford Healthcare Ltd. Medical DistributorsDistribution Services Distributes skin care and wound care products | Director/Board Member | 28/07/2009 |
Witham Contract Manufacturing Ltd.
 Witham Contract Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical and healthcare products | Director of Finance/CFO | 23/10/2008 |
Microscience Ltd.
 Microscience Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax | Director of Finance/CFO | 26/06/2005 |
York Pharma Plc
 York Pharma Plc Pharmaceuticals: MajorHealth Technology Develops and markets dermatological products | Director of Finance/CFO | - |
Oxford Immunotec Ltd.
 Oxford Immunotec Ltd. Medical SpecialtiesHealth Technology Develops and sells medical diagnostic products | Director of Finance/CFO | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
16
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
York Pharma Plc
York Pharma Plc Pharmaceuticals: MajorHealth Technology Develops and markets dermatological products | Health Technology |
Microscience Ltd.
Microscience Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, traveler's diarrhea, hepatitis B, and anthrax | Health Technology |
Witham Contract Manufacturing Ltd.
Witham Contract Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical and healthcare products | Health Technology |
Oxford Immunotec Ltd.
Oxford Immunotec Ltd. Medical SpecialtiesHealth Technology Develops and sells medical diagnostic products | Health Technology |
Crawford Healthcare Ltd.
Crawford Healthcare Ltd. Medical DistributorsDistribution Services Distributes skin care and wound care products | Distribution Services |
Sixth Element Capital LLP
Sixth Element Capital LLP Investment ManagersFinance Sixth Element Capital invests in cancer and oncology drug discovery research projects across Europe. The firm provides financing for growth capital requirements with an investment up to £50 million. | Finance |
Adorx Therapeutics Ltd.
Adorx Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research of new therapeutics for cancer based on modulation of the adenosine pathway | Commercial Services |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotech company that develops next generation CAR-T therapy | Commercial Services |
- Stock Market
- Insiders
- Ian Alexander Francis Miscampbell
